Novel self assembling nanoparticles for the oral administration of fondaparinux: Synthesis, characterization and in vivo evaluation

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 323-331

  Ralay Ranaivo, Bettina ^a   Desmaële, Didier ^a   Bianchini, Elsa P ^b   Lepeltier, Elise ^a   Bourgaux, Claudie ^a   Borgel, Delphine ^b   Pouget, Thierry ^c   Tranchant, Jean François ^c   Couvreur, Patrick ^a   Gref, Ruxandra ^a,d  

^a UNIV PARIS SUD   (France)

^b EA 4531 Ingenierie des Proteines de l'Hemostase A Potentiel Therapeutique   (France)

^c Parfums Christian Dior   (France)

^d INSTITUT DES SCIENCES MOLÉCULAIRES D ORSAY   (France)

Author keywords

Cationic squalenyl derivative; Fondaparinux; Nanoparticle; Self assembly

Indexed keywords

SELF ASSEMBLY;

FONDAPARINUX; IN-VIVO; ORAL ADMINISTRATION; SELF-ASSEMBLING;

NANOPARTICLES;

CATIONIC SQUALENYL DERIVATIVE; FONDAPARINUX; NANOCARRIER; POLYANION; SQUALENE DERIVATIVE; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; DRUG CARRIER; FIBRINOLYTIC AGENT; NANOPARTICLE; POLYSACCHARIDE; SQUALENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; AQUEOUS SOLUTION; ARTICLE; BLOOD FLOW; CHEMICAL INTERACTION; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROPHOBICITY; IN VIVO STUDY; MALE; MICROCAPSULE; NANOENCAPSULATION; NONHUMAN; RAT; STATIC ELECTRICITY; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD CLOTTING; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG FORMULATION; DRUG STABILITY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FIBRINOLYTIC AGENTS; INJECTIONS, INTRAVENOUS; MALE; NANOPARTICLES; PARTICLE SIZE; POLYSACCHARIDES; RATS; RATS, SPRAGUE-DAWLEY; SQUALENE;

EID: 84907695585     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.07.060     Document Type: Article

References (21)

1. S.M. Bates, I.A. Greer, I. Pabinger, S. Sofaer, J. Hirsh, and American College of Chest Physicians Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 8th edition Chest 133 2008 844S 886S
2. J.M. Herbert, M. Petitou, J.C. Lormeau, R. Cariou, J. Necciari, H.N. Magnani, P. Zandberg, R.G.M. van Amsterdam, C.A.A. van Boeckel, and D.G. Meuleman SR 90107/org 31540, a novel anti-factor Xa antithrombotic agent Cardiov. Drug Rev. 15 1997 1 26
3. A. Vetter, G. Perera, K. Leithner, G. Klima, and A. Bernkop-Schnürch Development and in vivo bioavailability study of an oral fondaparinux delivery system Eur. J. Pharm. Sc. 41 2010 489 497
4. N.A. Motlekar, and B.B.C. Youan The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins J. Control. Rel. 113 2006 91 101
5. K.A. Bauer, D.W. Hawkins, P.C. Peters, M. Petitou, J.M. Herbert, C.A.A. van Boeckel, and D.G. Meuleman Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors Cardiov. Drug. Rev. 20 2002 37 52
6. J. Meissonnier, N. Sicre, G. Sabate, G. Dubreucq, V. Nancy-Portebois, and M. Petitou Pharmaceutical oral dosage form containing a synthetic oligosaccharide WO 2011/073408 A2 2011
7. T.W. Leonard, D.C. Coughlan, and A. Cullen Pharmaceutical compositions of selective factor Xa inhibitors for oral administration WO 2011/120033 A1 2011
8. A. Ramadan, F. Lagarce, A. Tessier-Marteau, O. Thomas, P. Legras, L. Macchi, P. Saulnier, and J.P. Benoit Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study Int. J. Pharm. 422 2012 179 184
9. D. Desmaële, R. Gref, and P. Couvreur Squalenoylation: a generic platform for nanoparticular drug delivery J. Control. Rel. 161 2012 609 618
10. G.S. Kelly Squalene and its potential clinical uses Alter. Med Rev. 4 1999 29 36
11. P. Couvreur, B. Stella, L.H. Reddy, H. Hillaireau, C. Dubernet, D. Desmaële, S. Lepêtre-Mouelhi, F. Rocco, N. Dereuddre-Bosquet, and P. Clayette Squalenoyl nanomedicines as potential therapeutics Nano Lett. 6 2006 2544 2548
12. R. Paliwal, S.R. Paliwal, G.P. Agrawal, and S.P. Vyas Recent advances in search of oral heparin therapeutics Med. Res. Rev. 32 2012 388 409
13. P.Y. Hayes, B.P. Ross, B.G. Thomas, and I. Toth Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin Bioorg. Med. Chem. 14 2006 143 152
14. W. Sun, S. Mao, D. Mei, and T. Kissel Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin Eur. J. Pharm. Biopharm. 69 2008 417 425
15. W. Sun, S. Mao, Y. Wang, V.B. Junyaprasert, T. Zhang, L. Na, and J. Wang Bioadhesion and oral absorption of enoxaparin nanocomplexes Int. J. Pharm. 386 2010 275 281
16. D.Y. Lee, J. Lee, S. Lee, S.K. Kim, and Y. Byun Lipophilic complexation of heparin based on bile acid for oral delivery J. Control. Rel. 123 2007 39 45
17. H.T. Moon, Y.K. Lee, J.K. Han, and Y.A. Byun A novel formulation for controlled-release of heparin-DOCA conjugate dispersed as nanoparticles in polyurethane film Biomaterials 22 2001 281 289
18. E.E. van Tamelen, and T.J. Curphey Tetrahedron Lett. 1962 121 124
19. S. Sen, and G.D. Prestwich Trisnorsqualene alcohol, a potent inhibitor of vertebrate squalene epoxidase J. Am. Chem. Soc. 111 1989 1508 1510
20. P. Legrand, S. Lesieur, A. Bochot, R. Gref, W. Raatjes, G. Barratt, and C. Vauthier Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation Int. J. Pharm. 344 2007 33 43
21. T. Jung, W. Kamm, A. Breitenbach, E. Kaiserling, J.X. Xiao, and T. Kissel Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50 2000 147 160